Literature DB >> 22402344

Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Alexander M Herman1, Preeti J Khandelwal, G William Rebeck, Charbel E-H Moussa.   

Abstract

The transactivation DNA-binding protein (TDP-43) pathology is associated with fronto-temporal lobar dementia (FTLD) with ubiquitinated inclusions and some cases of Alzheimer's disease (AD). Proteolytic fragments of β-amyloid precursor protein (βAPP) are detected in AD as well as the cerebrospinal fluid (CSF) from FTLD and Amyotrophic Lateral Sclerosis (ALS) patients, suggesting alteration in APP processing. Because of the overlap in TDP-43 pathology between FTLD and AD, we sought to determine whether there is a relationship between TDP-43 and APP metabolism. We generated gene transfer models using lentiviral delivery of human TDP-43 and Aβ(1-42) into the rat primary motor cortex and examined their role 2 weeks post-injection. Expression of TDP-43 and/or Aβ(1-42) increase pro-inflammatory markers, including Interleukin (IL)-6, tumor necrosis factor (TNF-α), glial neurofibrillary proteins (GFAP) and ionized calcium binding adaptor molecule 1 (IBA-1). Lentiviral Aβ(1-42) up-regulates endogenous TDP-43 and promotes its phosphorylation, aggregation and cleavage into 35 kDa fragments. Inversely, lentiviral TDP-43 expression increases the levels and activity of β-secretase (BACE), accelerating production of APP C-terminal fragments (C99) and Aβ(1-40). Here we show that TDP-43 up-regulates APP metabolism and suggest a mechanistic link between TDP-43 and BACE.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402344      PMCID: PMC3434705          DOI: 10.1016/j.expneurol.2012.02.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  45 in total

1.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  β-amyloid triggers ALS-associated TDP-43 pathology in AD models.

Authors:  Alexander M Herman; Preeti J Khandelwal; Brenna B Stanczyk; G William Rebeck; Charbel E-H Moussa
Journal:  Brain Res       Date:  2011-03-02       Impact factor: 3.252

3.  Frontotemporal lobar degeneration: demographic characteristics of 353 patients.

Authors:  Julene K Johnson; Janine Diehl; Mario F Mendez; John Neuhaus; Jill S Shapira; Mark Forman; Dennis J Chute; Erik D Roberson; Catherine Pace-Savitsky; Manuela Neumann; Tiffany W Chow; Howard J Rosen; Hans Forstl; Alexander Kurz; Bruce L Miller
Journal:  Arch Neurol       Date:  2005-06

4.  Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss.

Authors:  G William Rebeck; Hyang-Sook Hoe; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

5.  Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.

Authors:  Felix Geser; Nicholas J Brandmeir; Linda K Kwong; Maria Martinez-Lage; Lauren Elman; Leo McCluskey; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2008-05

6.  Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology.

Authors:  Leo F McCluskey; Lauren B Elman; Maria Martinez-Lage; Vivianna Van Deerlin; Wuxing Yuan; Dana Clay; Andrew Siderowf; John Q Trojanowski
Journal:  Arch Neurol       Date:  2009-01

7.  Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

Authors:  Ian R A Mackenzie; Eileen H Bigio; Paul G Ince; Felix Geser; Manuela Neumann; Nigel J Cairns; Linda K Kwong; Mark S Forman; John Ravits; Heather Stewart; Andrew Eisen; Leo McClusky; Hans A Kretzschmar; Camelia M Monoranu; J Robin Highley; Janine Kirby; Teepu Siddique; Pamela J Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

8.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

9.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

10.  Parkin promotes intracellular Abeta1-42 clearance.

Authors:  Mark P Burns; Lihua Zhang; G William Rebeck; Henry W Querfurth; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2009-05-29       Impact factor: 6.150

View more
  21 in total

Review 1.  Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sami J Barmada
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 2.  The Role of TDP-43 in Alzheimer's Disease.

Authors:  Xiao-Long Chang; Meng-Shan Tan; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-06-17       Impact factor: 5.590

Review 3.  Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis.

Authors:  Mariana Pehar; Benjamin A Harlan; Kelby M Killoy; Marcelo R Vargas
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 4.  Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes.

Authors:  Katherine E Prater; Caitlin S Latimer; Suman Jayadev
Journal:  Glia       Date:  2021-09-24       Impact factor: 7.452

5.  Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).

Authors:  Michaeline L Hebron; Irina Lonskaya; Kaydee Sharpe; Puwakdandawe P K Weerasinghe; Norah K Algarzae; Ashot R Shekoyan; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

6.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

7.  Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis.

Authors:  Michaeline Hebron; Wenqiang Chen; Matthew J Miessau; Irina Lonskaya; Charbel E-H Moussa
Journal:  J Neurochem       Date:  2013-12-19       Impact factor: 5.372

Review 8.  The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.

Authors:  Gabriella MacDougall; Logan Y Brown; Boris Kantor; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

Review 9.  Molecular, functional, and pathological aspects of TDP-43 fragmentation.

Authors:  Deepak Chhangani; Alfonso Martín-Peña; Diego E Rincon-Limas
Journal:  iScience       Date:  2021-04-21

10.  TDP-43 and amyloid precursor protein processing: implications for Alzheimer's disease.

Authors:  David A Hicks
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.